(Reuters) – China’s National Medical Products Administration has approved domestic drugmaker Innovent Biologics’ weight control peptide injection’s entry into the market, the regulator said in a statement on Friday.
ADVERTISEMENT
A stock photo of a China's flag (Canva)
Previous Article
Comelec lifts suspension on Eric Yap’s proclamation as Benguet rep
Next Article
PH-US deal to fund technical aid for freight cargo railway project
Other News
Only 2 months left in Middle East crisis funds, Gatchalian warns
April 13, 2026
Duterte spouse seeks court relief from BIR tax record disclosure ...
April 13, 2026
Bulacan airport cited at OECD forum for global standards alignmen ...
April 13, 2026
Ramil Madriaga a ‘Trojan horse,’ may backfire on Duterte critics ...
April 13, 2026
Marcos cuts LPG, kerosene excise taxes to ease fuel costs under e ...
April 13, 2026
